Rheumatology Daily Report: 01/17/2024

Two phase I studies investigated the population pharmacokinetics and pharmacodynamics of cedirogant (ABBV-157) in healthy participants and participants with moderate to severe psoriasis. Cedirogant plasma concentrations and ex vivo interleukin 17A (IL-17A) inhibition were analyzed (1). The studies found comparable pharmacokinetics between healthy participants and participants with psoriasis. The exposure-response relationship indicated saturable inhibition of IL-17A, supporting dose selection for a Phase 2 dose-ranging study in patients with psoriasis.

Reference

Maier CS, Eckert D, Laroux FS, Hew KM, Suleiman AA, Liu W, Mohamed MF. Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin-17A Inhibition in Two Phase I Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis. Clin Pharmacol Drug Dev. 2024 Jan 17. doi: 10.1002/cpdd.1377. Epub ahead of print. PMID: 38231873.